Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Health Care Costs at End-of-Life for Patients with Idiopathic Pulmonary Fibrosis: Evaluation of a Pilot Multidisciplinary Clinic.

Kalluri M, Lu-Song J, Younus S, Nabipoor M, Richman-Eisenstat J, Ohinmaa A, Bakal JA.

Ann Am Thorac Soc. 2020 Mar 20. doi: 10.1513/AnnalsATS.201909-707OC. [Epub ahead of print]

PMID:
32197048
2.

Clinical implications of ANCA positivity in idiopathic pulmonary fibrosis patients.

Suarez-Cuartin G, Molina-Molina M.

Breathe (Sheff). 2020 Mar;16(1):190321. doi: 10.1183/20734735.0321-2019.

3.

Patients' and Healthcare Professionals' Experiences of Idiopathic Pulmonary Fibrosis Treatment with the Pirfenidone 801 mg Tablet Formulation: A Multinational Survey.

Lancaster LH, Valenzuela C, Mason W, Neurohr C, Ripamonti E, Kirchgaessler KU, Cottin V.

Pulm Ther. 2020 Mar 19. doi: 10.1007/s41030-020-00111-y. [Epub ahead of print]

PMID:
32193713
4.

Pirfenidone in chronic lung allograft dysfunction: a single cohort study.

Bennett D, Lanzarone N, Fossi A, Perillo F, De Vita E, Luzzi L, Paladini P, Bargagli E, Sestini P, Rottoli P.

Panminerva Med. 2020 Mar 19. doi: 10.23736/S0031-0808.19.03840-0. [Epub ahead of print]

PMID:
32192319
5.

[Characteristics and clinical significance of pulmonary function test and KL-6 in ASSD-ILD and IPF].

Sun D, Cheng Z, Jiang TC, Li PF, Jia LQ, Wang TT, Zheng CP, Li Y, Duo MJ.

Zhonghua Yi Xue Za Zhi. 2020 Mar 17;100(10):748-752. doi: 10.3760/cma.j.cn112137-20191008-02166. Chinese.

PMID:
32192286
6.

Sphingosine Kinase 1/S1P Signaling Contributes to Pulmonary Fibrosis by Activating Hippo/YAP Pathway and Mitochondrial Reactive Oxygen Species in Lung Fibroblasts.

Huang LS, Sudhadevi T, Fu P, Punathil-Kannan PK, Ebenezer DL, Ramchandran R, Putherickal V, Cheresh P, Zhou G, Ha AW, Harijith A, Kamp DW, Natarajan V.

Int J Mol Sci. 2020 Mar 17;21(6). pii: E2064. doi: 10.3390/ijms21062064.

7.

Supplemental Content

Loading ...
Support Center